Relmada Therapeutics (RLMD) Assets Average (2013 - 2026)

Relmada Therapeutics (RLMD) has reported Assets Average for 14 consecutive years, with $164.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 348.13% year-over-year to $164.7 million; the TTM figure through Mar 2026 stood at $164.7 million (up 348.13% YoY), while the FY2025 annual figure was $69.9 million, down 2.48% from the prior year.
• Assets Average rose to $164.7 million in Q1 2026 per RLMD's latest filing, from $54.4 million in the prior quarter.
• Across five years, Assets Average topped out at $224.6 million in Q1 2022 and bottomed at $18.0 million in Q3 2025.
• Historically, Assets Average has averaged $111.2 million across 5 years, with a median of $103.4 million in 2023.
• Annual changes were most pronounced in 2025 — Assets Average plunged 71.6% — and 2026, when it surged 348.13%.
• Relmada Therapeutics' Assets Average stood at $170.0 million in 2022, then sank by 39.21% to $103.4 million in 2023, then slumped by 50.87% to $50.8 million in 2024, then climbed by 7.23% to $54.4 million in 2025, then jumped by 202.5% to $164.7 million in 2026.
• Business Quant data shows RLMD's Assets Average at $164.7 million in Q1 2026, $54.4 million in Q4 2025, and $18.0 million in Q3 2025.